Malin Corporation | MLC - Selling And Administration Expenses

Stock Price
7.60
Daily Change
0 0%
Monthly
0%
Yearly
-24.00%
Q1 Forecast
7.37

Malin Corporation reported EUR1.1M in Selling and Administration Expenses for its fiscal semester ending in December of 2024.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
Alaunos Therapeutics USD 585K 260K Sep/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Avita Medical AUD 19.03M 1.95M Dec/2025
Dianthus Therapeutics USD 8.2M 669K Sep/2025
Eurofins Scientific SE EUR 0 0 Jun/2023
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
IQVIA Holdings USD 468M 46M Dec/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Moderna USD 308M 40M Dec/2025
Organon & Co USD 399M 54M Sep/2025
Ovoca Bio EUR 2.96M 8K Jun/2022
Revvity USD 251.73M 9.82M Dec/2025
Tectonic Therapeutic USD 4.96M 190K Sep/2025
Viatris USD 1.03B 144.1M Dec/2025
Xeris Pharmaceuticals USD 46.46M 2.07M Sep/2025